Orpyx Receives Funding Support From WINN Initiative

Western Innovation (WINN) Initiative Helps Foster Commercialization of Western Canadian Projects

Calgary, AB July 2, 2014 - Orpyx Medical Technologies Inc. has been announced as one of the twenty-seven companies in western Canada to receive funding under the Western Innovation (WINN) Initiative. WINN is a government program committed to creating jobs, promoting economic growth, and maintaining Canada’s competitive advantage in the global marketplace.  In Alberta, WINN will be funding eleven projects totaling $6.81 million to support the advancement of a healthy economy.

This investment will help support development of Orpyx’s predictive data analytics for new markets like athletics.  “We are thrilled to receive the support from WINN.  This allows us to innovate faster toward a broader footprint of uses for our wearable technology platform,” states Lew Turnquist, President of Orpyx.

The Honourable Michelle Rempel, Minister of State for Western Economic Diversification said, “I am proud to support programs such as the WINN Initiative, which will assist small and medium-sized enterprises in Western Canada in bringing their ideas into the global marketplace.  Through WINN we are filling a funding gap identified by Canadian business and re-affirming our government’s commitment to providing opportunities for jobs and growth.”

About Western Innovation (WINN) Initiative:

Over its 5-year span WINN will provide up to $100 million in repayable assistance to western small- and medium-seized enterprises (SMEs).  Under WINN, SMEs can apply for funding for a variety of tasks that are essential in taking a product from the research and development stage to the market, such as: product testing and technology demonstrations, equipment purchases and installation, regulatory approval, marketing, and intellectual property protection.

About Orpyx Medical Technologies:

Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, lack of circulation, numbness, infection and ulcers in the feet, also known as peripheral neuropathy.  The diabetic foot ulcer is one of the most devastating side effects of diabetes, occurring in upwards of 15-25% of all diabetic patients over the course of their disease.  The inability to sense and respond to tissue damage can lead to the development of blisters and ulcers, which can lead to surgical amputation.  Orpyx was born out of a profound desire to find a preventative rather than reactionary solution to this problem.

Orpyx develops sensor-based technologies that address the growing demand for self-monitoring devices to better manage chronic medical conditions.  Our products focus on patient empowerment and prevention for better outcomes.

For more information, please contact:

Stephanie Zakala
Marketing & Inside Sales Manager, Orpyx Medical Technologies Inc.

Download the PDF Press Release here.

Stephanie Zakala
Stephanie Zakala